coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Denton PCN, Tameside (LAD) · Health Inequalities Profile

    PCN U53900 · NHS Greater Manchester Integrated Care Board · 6 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    53,505

    Registered population

    61.3% aged 18–64

    18.5%

    Aged 65+

    ICB 14.9% · England 17.9%

    30.3%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~19,466

    Core20 residents (est.)

    Resident basis; registered basis ~16,533 · see page 3

    9,082

    Hypertension register

    +5.45% in 3 yrs · England +5.60%

    470

    SMI register

    20% of Tameside (LAD)'s

    1,546

    COPD register

    Reviews +4.19% in 3 yrs

    Forecast to 2030

    10,424

    Hypertension patients, 2030

    +1,342 on today

    74.9%

    QRISK ≥20% on statins, 2030

    +1.64pp over 3 yrs

    4.9%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    57.7%
    Annual asthma reviews lag and are falling.

    Coverage is below England (65.7%) after a -5.4% 2023 to 2025 change (England +4.4%), leaving a scale indicator of 1,468 unreviewed patients.

    60.3%
    Under-80s hypertension blood pressure control trails.

    Control is below England (67.8%) with a -0.1% 2023 to 2025 change (England +3.2%) and 64.7% overall treated to target, suggesting titration audit.

    88.5%
    SMI checks and lipid therapy exceed England.

    Annual SMI blood pressure checks beat England (83.4%) after rising +8.4 pp over 2023 to 2025, alongside 71.5% QRISK lipid therapy (England 63.6%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Older adults comprise 18.5% of registered patients, exceeding borough and ICB comparators

    Across 53,505 registered patients, Denton PCN has an older age profile: 18.5% (9,877 patients) are aged 65+, above Tameside (LAD) (16.4%), NHS Greater Manchester Integrated Care Board (14.9%) and England (17.9%). Children aged 0-17 represent 20.3% (10,852 patients), below Tameside (LAD) (21.3%) and NHS Greater Manchester Integrated Care Board (21.8%) but above England (19.6%). Census estimates record 0.1% Gypsy or Irish Traveller and 0.1% Roma residents. Projected list growth to 2030 is 1.6% (methodology unverified; Tameside (LAD) 1.4%, England 2.3%).

    Age profile

    0–1720.3%
    18–6461.3%
    65+18.5%

    65+: ICB 14.9%, England 17.9%

    Older people · falls rows are Tameside (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Tameside LA)2,0472,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)83.8%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)56.0%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Tameside LA)1,0451,0219552024/25
    Falls deaths, all ages, per 100,000 (Tameside LA)32.518.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation averages 30.3% across the PCN but spans 39.3 percentage points between practices

    Core20 registered share is 30.3%, above England (21.0%) but below Tameside (LAD) (40.9%) and NHS Greater Manchester Integrated Care Board (40.7%). Weighted practice share is 30.9% (a 0.63 pp reconciliation difference), while estimated resident Core20 counts 19,466. Practice concentration spans 39.3 pp, led by Denton Medical Practice (50.7%) and Guide Bridge Medical Practice (49.0%), down to Medlock Vale Medical Practice (11.4%). By volume, Millgate Healthcare Partnership holds 7,517 estimated Core20 patients (36.2% share). Resource allocation could balance high-share outreach against high-volume list capacity.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Denton Medical50.7% · 4,338 patients
    Guide Bridge49.0% · 2,149 patients
    Millgate36.2% · 7,517 patients
    Droylsden Medical14.8% · 671 patients
    Market Street12.8% · 1,011 patients
    Medlock Vale11.4% · 847 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    470

    SMI register

    0.88% recorded prevalence

    367

    Learning disability register

    0.69% recorded prevalence

    10

    Care homes, 313 beds

    In the PCN catchment

    9.7%

    Provide unpaid care

    Tameside (LAD), Census 2021

    Learning disability prevalence is 0.7% (367 patients; Tameside (LAD) 0.7%, England 0.6%) and severe mental illness is 0.9% (470 patients; Tameside (LAD) 1.0%, England 1.0%). Catchment sites include 10 care homes with 313 beds.

    Severe mental illness: physical health checks

    Recorded SMI blood pressure checks reach 88.5% (England 83.4%) and BMI checks reach 87.0% (England 82.1%). Psychosis alcohol recording is 88.2% (England 81.8%). While recorded individual elements exceed national benchmarks, uncaptured components mean full health check bundles cannot be assumed.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    9,082

    Hypertension register

    +5.45%

    Register growth, 3 yrs

    Tameside (LAD) +5.50% · England +5.60%

    −0.04pp

    BP control, under 80

    ≤140/90 · +4.20pp aged 80+

    +1,342

    More patients by 2030

    Forecast 10,424 (18.86%)

    Hypertension case-finding and control

    Hypertension recorded prevalence is 17.0% (9,082 patients), above England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%) but below Tameside (LAD) (17.4%), giving an unadjusted benchmark register gap range of -933 to +219 patients. Recent blood pressure readings reach 87.1% (England 90.0%; Tameside (LAD) 89.2%; ICB 90.3%). Overall treated to target is 64.7% (England 70.3%; ICB 71.4%), while under-80s blood pressure control is 60.3% (England 67.8%; Tameside (LAD) 65.2%; ICB 68.6%), falling 0.1% over 2023 to 2025 (England +3.2%). Crude prevalence does not establish undiagnosed disease, and denominators include personalised care adjustments. Blood pressure control lags national benchmarks, showing a clinical priority to focus on treatment titration and structured recall.

    Lipids and statins

    Lipid-lowering therapy for QRISK ≥ 20% is 71.5% (Tameside (LAD) 69.2%; ICB 67.0%; England 63.6%), while chronic kidney disease coverage is 82.9% (Tameside (LAD) 78.2%; ICB 73.6%; England 70.3%). Denominators include personalised care adjustments. Therapy coverage exceeds all benchmarks, showing strong primary and secondary prevention prescribing that practices should sustain.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026118,782£2.00£1.94£1.86£237,564
    Cardiovascular (all), 2025167,894£2.63£3.15£3.33£441,561

    In 2026, Denton PCN prescribed 118,782 lipid-regulating items (£237,564 spend) at £2.00 per item (Tameside (LAD) £2.01; ICB £1.94; England £1.86). The PCN spends £16,629 more than at England's unit cost across 118,782 items, though unit cost does not indicate efficiency. Higher unit costs than England suggest an operational opportunity to review formulary choices and product mix.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −5.36%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −4.26%

    Asthma prevalence, PCN 3-yr % change

    Asthma prescribing in 5-19s is 2,269 items per 1,000 (England 1,488; Tameside (LAD) 2,233). Annual asthma reviews stand at 57.7% (England 65.7%), falling 5.4% over 2023 to 2025 (England +4.4%), leaving a scale indicator of 1,468 unreviewed patients across the 3,469 register. COPD prevalence is 2.9% (England 1.9%), but reviews lag at 69.5% (England 76.4%). High prescribing alongside trailing reviews may reflect review or preventative shortfalls, not verified locally.

    Cancer register and children's immunisation

    The cancer register records 2,138 patients (4.0% prevalence; England 3.8%). In childhood immunisations, 6-in-1 coverage at 12 months is 92.9% (England 91.0%), but MMR1 at 24 months trails at 84.7% (England 88.3%). By age 5, MMR1 reaches 93.5% but MMR2 drops to 83.1% (a 10.4 pp difference), while the 4-in-1 booster is 78.2% (England 80.9%), below the 95.0% standard by 16.8 pp.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months92.9%

    England 91.0%

    6-in-1 complete primary course at 24 months89.3%

    England 92.2%

    MMR dose 1 at 24 months84.7%

    England 88.3%

    MMR dose 2 at age 583.1%

    England 82.8%

    4-in-1 pre-school booster at age 578.2%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    In 2022, across NHS Greater Manchester ICB, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed early (stage 1 or 2), against 55.3% in England. This sits 19.4 pp below the 75.0% national ambition by 2028, representing about 2,270 extra early cases across the ICB. Stage was known for 70.8% of 16,492 cancers. System staging does not reflect PCN performance. Within Denton PCN, cervical screening in women aged 25 to 49 is 68.3% (England 66.8%), but fell 1.7% over 2023 to 2025 (England -1.0%), dropping to 59.7% at Market Street Medical Practice.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In Jul 2026 (provisional), Tameside and Glossop Integrated Care NHS Foundation Trust achieved 76.8% on the cancer 62-day referral to treatment standard (distance of -8.2 pp to the 85.0% standard), above Stockport NHS Foundation Trust (74.7%), Manchester University NHS Foundation Trust (72.8%), NHS Greater Manchester Integrated Care Board (75.7%) and England (71.2%). On the 28-day faster diagnosis standard, the trust reached 82.5% against the 75.0% standard (Stockport 83.2%, Manchester University 80.1%, ICB 79.5%, England 79.3%). For Jul 2026 diagnostic waits of 6+ weeks, the trust recorded 0.0% for MRI and 0.2% for CT (England 21.4% and 9.9%).

    Pathways within standard (%)Tameside and Glossop Integrated CareManchesterStockportGreater Manchester ICBEngland
    28-day faster diagnosis (75%)82.4880.0683.2179.5379.32
    31-day treatment (96%)96.2592.5497.3996.4992.50
    62-day referral to treatment (85%)76.7772.8574.6775.7371.16
    Diagnostic waits over 6 weeks (%)Tameside and Glossop Integrated CareManchesterStockportEngland
    MRI0.0011.681.4121.40
    CT0.1814.662.939.92
    Echocardiography0.004.9117.4628.48
    Colonoscopy1.514.515.5330.83
    Gastroscopy5.4529.355.3129.02
    All 15 DM01 tests0.808.9814.0823.14
    Community services activityTameside residentsGreater Manchester ICB
    Care contacts50,685573,310
    Referrals9,45094,470
    Patients with a contact15,790183,535

    Community services (residents of Tameside), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65+ accounted for 52.1% of community service contacts among Tameside residents (26,410 of 50,685 total contacts). These dataset figures reflect borough-wide resident activity rather than PCN-specific delivery, illustrating substantial community health service use by older populations across the borough.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    In 2025/26, QOF overall achievement was 88.9% at Guide Bridge Medical Practice and 100.0% at Market Street Medical Practice (England 92.5%). QOF clinical-domain achievement was 97.4% at Denton Medical Practice (England 97.1%). QOF vaccination and immunisation-domain achievement was 15.6% at Guide Bridge Medical Practice and 100.0% at Market Street Medical Practice (England 55.2%).

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Market Street10912.865.8%77.8%82.8%
    Medlock Vale10111.461.0%76.7%80.8%
    Droylsden Medical10214.843.7%68.0%69.5%
    Denton Medical12650.752.7%55.8%68.5%
    Millgate11736.246.8%78.3%67.7%
    Guide Bridge8949.030.2%55.4%60.5%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNTameside (LAD)AssetPCNTameside (LAD)
    Care homes (catchment)10 (313 beds)n/aSchools (catchment)54n/a
    Children's centres616Places of worship29104
    Libraries47Homelessness support (VCS)12
    Primary schools (LA maintained)622Primary academies1546

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review and inhaler recall

    Annual asthma reviews are 57.7% (Tameside (LAD) 62.2%; England 65.7%), falling 5.4% over 2023 to 2025 (England +4.4%), leaving a scale indicator of 1,468 unreviewed patients across the 3,469 register. For discussion: run structured asthma recall using a single template, offering after-school slots and reviewing repeat inhaler prescribing. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Under-80s hypertension titration and recall

    Across 9,082 hypertension patients, under-80s blood pressure control is 60.3% (Tameside (LAD) 65.2%; ICB 68.6%; England 67.8%), falling 0.1% over 2023 to 2025 (England +3.2%), while overall treated to target is 64.7% (England 70.3%). Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Dementia register coding and case-finding audit

    Dementia prevalence is 0.7% (350 patients; Tameside (LAD) 0.8%; England 0.8%) and fell 3.1% over 2023 to 2025 (England +6.0%), giving an unadjusted benchmark gap range of +68 to +69 patients. For discussion: audit clinical records for uncoded memory clinic letters or cognitive assessments and review care-home case-finding routes. Low cost, quick to run.

    Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.

    Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older adult frailty coordination (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Two-track Core20 resource allocation (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Sustain SMI physical health checks (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension titration and recall review (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall outreach (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening uptake review (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Practice telephony and triage review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Structured asthma review and inhaler recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 PopulationCore20PLUS5 respiratoryPCN
    Option 2 · Under-80s hypertension titration and recall (p12)Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Hypertension patients treated to targetCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Dementia register coding and case-finding audit (p12)Dementia register · Dementia: QOF prevalence · Aged 65+66.7% diagnosis ambition · 95% care plan 2027PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15